The NHLBI Phase IIB Bridge Award (RFA-HL-23-009) and the NHLBI Phase IIB Small Market Award (RFA-HL-23-008) Programs can provide up to $3 Million over 3 years to continue the commercialization of novel products in the NHLBI mission space, specifically towards the completion of milestones necessary to achieve regulatory approval. This work must represent extension of work completed under an SBIR Phase II award. This funding opportunity also encourages business relationships between small businesses and third-part investors or strategic partners. The evidence of secured third party investment will be strongly considered in review of the applications and in making funding decisions.
NIH support is particularly important for products that have important but small markets. The National Center for Advancing Translational Sciences (NCATS) will consider co-funding awards in the small markets program that address rare diseases and, in particular, platforms that address multiple rare diseases. Applicants who believe their technologies are relevant to the small market opportunity are encouraged to read this opportunity for specific definitions and areas of interest.
Next receipt date: Monday, Jan. 28